Trial Profile
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Tremelimumab (Primary)
- Indications Bladder cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 05 Jan 2024 Results for safety and efficacy, published in the Cancer
- 10 Apr 2023 Planned End Date changed from 1 Feb 2023 to 1 Apr 2023.
- 08 Dec 2022 Planned End Date changed from 1 Oct 2023 to 1 Feb 2023.